| 1 |
33184472 | Cytochrome P450 1A2 overcomes nuclear factor kappa B-mediated sorafenib resistance in hepatocellular carcinoma. | 2021 Jan |
1 |
| 2 |
33397254 | Metabolism and Mechanism of Human Cytochrome P450 Enzyme 1A2. | 2021 |
1 |
| 3 |
33590212 | Micropatterned Coculture With 3T3-J2 Fibroblasts Enhances Hepatic Functions and Drug Screening Utility of HepaRG Cells. | 2021 Apr 27 |
1 |
| 4 |
31863871 | Comparison of the toxicity of sulfur mustard and its oxidation products in vitro. | 2020 Mar 15 |
1 |
| 5 |
32037158 | Establishment of a primary human hepatocyte spheroid system for evaluating metabolic toxicity using dacarbazine under conditions of CYP1A2 induction. | 2020 Apr |
4 |
| 6 |
32350061 | Enrichment-free High-throughput Liquid Chromatography-Multiple-Reaction Monitoring Quantification of Cytochrome P450 Proteins in Plated Human Hepatocytes Direct from 96-Well Plates Enables Routine Protein Induction Measurements. | 2020 Jul |
1 |
| 7 |
32558923 | Effect of High-Dose Esomeprazole on CYP1A2, CYP2C19, and CYP3A4 Activities in Humans: Evidence for Substantial and Long-lasting Inhibition of CYP2C19. | 2020 Dec |
1 |
| 8 |
30865484 | Cytotoxicity of safrole in HepaRG cells: studies on the role of CYP1A2-mediated ortho-quinone metabolic activation. | 2019 Dec |
2 |
| 9 |
31164617 | Study Protocol for a Pilot, Open-Label, Prospective, and Observational Study to Evaluate the Pharmacokinetics of Drugs Administered to Patients during Extracorporeal Circulation; Potential of In Vivo Cytochrome P450 Phenotyping to Optimise Pharmacotherapy. | 2019 May 13 |
1 |
| 10 |
31472121 | CYP1A2 Downregulation by Obeticholic Acid: Usefulness as a Positive Control for the In Vitro Evaluation of Drug-Drug Interactions. | 2019 Dec |
2 |
| 11 |
29063606 | Harnessing Meta-analysis to Refine an Oncology Patient Population for Physiology-Based Pharmacokinetic Modeling of Drugs. | 2018 Feb |
1 |
| 12 |
29357810 | Cytochrome P450 1A2 Messenger RNA is a More Reliable Marker than Cytochrome P450 1A2 Activity, Phenacetin O-Deethylation, for Assessment of Induction Potential of Drug-Metabolizing Enzymes Using HepaRG Cells. | 2018 |
3 |
| 13 |
29469947 | Evaluation of the metabolic capability of primary human hepatocytes in three-dimensional cultures on microstructural plates. | 2018 Apr |
1 |
| 14 |
30347615 | Optimized protocol for induction of cytochrome P450 enzymes 1A2 and 3A4 in human primary-like hepatocyte cell strain HepaFH3 to study in vitro toxicology. | 2018 |
1 |
| 15 |
28291036 | Potential Mechanisms of Hematological Adverse Drug Reactions in Patients Receiving Clozapine in Combination With Proton Pump Inhibitors. | 2017 Mar |
1 |
| 16 |
25600204 | Human HepaRG Cells can be Cultured in Hanging-drop Plates for Cytochrome P450 Induction and Function Assays. | 2015 |
1 |
| 17 |
26614990 | In vitro inhibitory effects of plumbagin, the promising antimalarial candidate, on human cytochrome P450 enzymes. | 2015 Nov |
1 |
| 18 |
24553381 | Evaluation of 23 lots of commercially available cryopreserved hepatocytes for induction assays of human cytochromes P450. | 2014 May |
1 |
| 19 |
24752503 | Aggregate culture of human embryonic stem cell-derived hepatocytes in suspension are an improved in vitro model for drug metabolism and toxicity testing. | 2014 Jul |
1 |
| 20 |
21885687 | Cocktail approach for in vivo phenotyping of 5 major CYP450 isoenzymes: development of an effective sampling, extraction, and analytical procedure and pilot study with comparative genotyping. | 2012 Aug |
1 |
| 21 |
22673034 | Evaluation of human embryonic stem cell-derived hepatocyte-like cells for detection of CYP1A inducers. | 2012 |
1 |
| 22 |
21277363 | Involvement of CYP3A4/5 and CYP2D6 in the metabolism of aconitine using human liver microsomes and recombinant CYP450 enzymes. | 2011 Apr 10 |
1 |
| 23 |
21555507 | Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. | 2011 Aug |
1 |
| 24 |
20019244 | Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells. | 2010 Mar |
1 |
| 25 |
21208171 | The use of HepaRG and human hepatocyte data in predicting CYP induction drug-drug interactions via static equation and dynamic mechanistic modelling approaches. | 2010 Dec |
1 |
| 26 |
18502397 | Omeprazole transactivates human CYP1A1 and CYP1A2 expression through the common regulatory region containing multiple xenobiotic-responsive elements. | 2008 Jul 1 |
6 |
| 27 |
16041547 | Cytochrome P450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction. | 2005 Sep |
1 |
| 28 |
16044115 | Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. | 2005 Aug |
2 |
| 29 |
16248835 | Effect of omeprazole on the hydroxylation of warfarin enantiomers in human: in-vitro studies with liver microsomes and cDNA-expressed cytochrome P450 isozymes. | 2005 Oct |
1 |
| 30 |
15025747 | Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. | 2004 Apr |
1 |
| 31 |
15119530 | Omeprazole treatment: genotoxicity biomarkers, and potential to induce CYP1A2 activity in humans. | 2004 Mar |
2 |
| 32 |
15681896 | Effects of NO-1886 (Ibrolipim), a lipoprotein lipase-promoting agent, on gene induction of cytochrome P450s, carboxylesterases, and sulfotransferases in primary cultures of human hepatocytes. | 2004 Dec |
1 |
| 33 |
12623754 | Time-dependent transcriptional induction of CYP1A1, CYP1A2 and CYP1B1 mRNAs by H+/K+ -ATPase inhibitors and other xenobiotics. | 2003 Feb |
1 |
| 34 |
12806570 | Omeprazole reduces clozapine plasma concentrations. A case report. | 2003 May |
2 |
| 35 |
12040753 | Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. | 2002 May |
1 |
| 36 |
12445035 | Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2. | 2002 Nov |
8 |
| 37 |
12451287 | Influence of the urine flow rate on some caffeine metabolite ratios used to assess CYP1A2 activity. | 2002 Dec |
1 |
| 38 |
10078840 | Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. | 1999 Jan |
1 |
| 39 |
10100022 | Species differences in hepatocyte induction of CYP1A1 and CYP1A2 by omeprazole. | 1999 Feb |
2 |
| 40 |
10584979 | Omeprazole weakly inhibits CYP1A2 activity in man. | 1999 Nov |
4 |
| 41 |
9246016 | The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S-mephenytoin. | 1997 Jul |
2 |
| 42 |
8930576 | Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. | 1996 Oct |
1 |
| 43 |
7927253 | Specific and dose-dependent enzyme induction by omeprazole in human beings. | 1994 Nov |
2 |
| 44 |
8085279 | Omeprazole does not enhance the metabolism of phenacetin, a marker of CYP1A2 activity, in healthy volunteers. | 1994 Jun |
1 |
| 45 |
8162667 | Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test. | 1994 Apr |
2 |
| 46 |
8169844 | Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. | 1994 Apr |
1 |
| 47 |
1426869 | Induction of cytochrome P450IA genes (CYP1A) by omeprazole in the human alimentary tract. | 1992 Nov |
1 |
| 48 |
1490825 | Dose dependent induction of CYP1A2 activity by omeprazole (Antra). | 1992 Nov |
2 |
| 49 |
1505152 | Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. | 1992 Aug |
1 |